...
首页> 外文期刊>APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica >Induction of specific cell‐mediated immune responses and protection in BALB/c mice by vaccination with outer membrane vesicles from a Brucella melitensis Brucella melitensis human isolate
【24h】

Induction of specific cell‐mediated immune responses and protection in BALB/c mice by vaccination with outer membrane vesicles from a Brucella melitensis Brucella melitensis human isolate

机译:来自Brucella Melitensis Brucella Melitensis人分离物的外膜囊泡的疫苗接种,诱导特定细胞介导的免疫应答和BALB / C小鼠的保护

获取原文
获取原文并翻译 | 示例
           

摘要

Brucellosis is a worldwide bacterial zoonosis caused by Brucella spp. No approved vaccine is available for human use against the disease. In this study, outer membrane vesicles ( OMV s) from a Brucella melitensis biovar 1 human isolate obtained in Iran were used to immunize BALB /c mice (n?=?12) by 2 intramuscular injections with a 2‐week interval. Another group of 12 mice was used as non‐vaccinated controls. Two weeks after the last vaccination, six mice of each group were sacrificed, and proliferation and interferon gamma ( IFN γ) production responses of their splenocytes were evaluated following in vitro stimulation with killed Brucella cells. The other mice were challenged with the virulent B.?melitensis isolate. Two weeks later, mice were killed and spleens were cultured to determine the number of the challenge strain. The results showed proliferative response and IFN γ production of splenocytes from vaccinated mice (stimulation index: 2.18?±?0.57, and 1519.35?±?10.70?pg/mL, respectively) were significantly higher than those of control mice (stimulation index: 1.02?±?0.02, and 210.01?±?17.58?pg/mL, respectively). Numbers of the challenge strain in spleens of vaccinated mice were also significantly less than those in the controls with 1.6 units of protection. Our study revealed vaccination with OMV s of the B.?melitensis isolate could induce specific immune responses and protection against infection in the mouse model suggesting their potential application for active immunization against brucellosis.
机译:布鲁氏菌病是由布鲁氏菌SPP引起的全球细菌性毒病症。没有批准的疫苗可用于对这种疾病的人类使用。在该研究中,来自伊朗的Brucella Melitensis Biovar 1人分离物的外膜囊泡(OMV S)用于将BALB / C小鼠(N 2 =β12)免疫2周间隔2周的间隔。将另一组12只小鼠用作非接种疫苗的对照。在最后一次疫苗接种后两周,处死六只小鼠,并在体外刺激用杀死的布鲁氏细胞进行体外刺激后评估其脾细胞的增殖和干扰素γ(IFNγ)的产生反应。其他小鼠用毒力B.?melitensis孤立攻击。两周后,杀死小鼠,培养脾脏以确定攻击菌株的数量。结果表明,来自接种疫苗的小鼠的脾细胞的增殖反应和IFNγ产生(刺激指数:2.18?±0.57和1519.35?±10.70·pg / ml)显着高于对照小鼠(刺激指数:1.02 ?±0.02和210.01?±17.58?pg / ml)。接种疫苗的小鼠脾脏的挑战菌株的数量也明显小于对照组的1.6单位保护。我们的研究揭示了B.?melitensis分离物的OMV S疫苗接种可以诱导特定的免疫应答和对小鼠模型中感染的保护,这表明他们潜在应用于对布鲁氏菌病的主动免疫施用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号